Travere Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Travere Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Travere Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Travere Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Travere Therapeutics Inc (Travere) is a biopharmaceutical company that identifies, develops, and commercializes medicines for rare kidney and metabolic diseases. The company's therapeutic areas focus on IgA Nephropathy (IgAN); Focal Segmental Glomerulosclerosis (FSGS); Classical Homocystinuria (HCU), and Cystinuria. Its major products include Filspari (sparsentan), which is used to slow kidney function decline in adults with primary IgA Nephropathy (IgAN). The company also distributes Thiola for the treatment of cystinuria. It collaborates with the rare disease community and healthcare providers to ensure broad access to its therapies. Travere markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in the US and Ireland. Travere is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 300, 3611 Valley Centre Drive, San Diego, California, 92130
Website
www.travere.com
Telephone
1 888 9697879
No of Employees
497
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TVTX (NASD)
Revenue (2024)
$490.7M
110.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
92.1%
(2024 vs 2023)
Market Cap*
$5.4B
Net Profit Margin (2024)
XYZ
96.2%
(2024 vs 2023)
* As of and is in US$
Travere Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Sparsentan: To slow the kidney function decline in adults with primary IgAN who are at risk of disease progression | Filspari |
| IgA Nephropathy(IgAN) | Totalcare |
| Focal Segmental Glomerulosclerosis(FSGS) | Thiola |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In May, the company received regulatory acceptance of the supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS) by the US FDA. |
| 2025 | Regulatory Approval | In April, the company and CSLVifor received approval from the European Commission for standard marketing authorization (MA) for Filspari used in adults with primary IgA nephropathy with a urine protein excretion of more than 1.0 g/day. |
| 2024 | Regulatory Approval | In October, the company and CSL Vifor secured temporary marketing authorization from Swissmedic for FILSPARI to treat adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day. |
Competitor Comparison
| Key Parameters | Travere Therapeutics Inc | Eli Lilly and Co | AstraZeneca Plc | Novartis AG | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | Germany |
| City | San Diego | Indianapolis | Cambridge | Basel | Leverkusen |
| State/Province | California | Indiana | Cambridgeshire | Basel-Stadt | Nordrhein-Westfalen |
| No. of Employees | 497 | 50,605 | 96,100 | 75,267 | 87,757 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eric Dube, PhD | President; Chief Executive Officer; Director | Executive Board | 2019 | 53 |
| Christopher Cline | Chief Financial Officer | Senior Management | 2022 | 42 |
| Elizabeth E. Reed | Secretary; General Counsel; Chief Legal Officer | Senior Management | 2017 | 55 |
| Angela Giannantonio | Chief People Officer | Senior Management | - | - |
| Jula Inrig, MD | Chief Medical Officer | Senior Management | 2022 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer